Effect of benfotiamine on advanced glycation endproducts and markers of endothelial dysfunction and inflammation in diabetic nephropathy

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Alkhalaf, Alaa ^a,b   Kleefstra, Nanne ^a,b,c   Groenier, Klaas H ^a,b   Bilo, Henk J G ^a,b   Gans, Reinold O B ^a   Heeringa, Peter ^a   Scheijen, Jean L ^d   Schalkwijk, Casper G ^d   Navis, Gerjan J ^a   Bakker, Stephan J L ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b ISALA HOSPITAL   (Netherlands)

^c LANGERHANS MEDICAL RESEARCH GROUP   (Netherlands)

^d MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

5 HYDRO 5 METHYLIMIDAZOLONE; ADVANCED GLYCATION END PRODUCT; ALBUMIN; BENFOTIAMINE; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CREATININE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 1; MYELOPEROXIDASE; N (CARBOXYETHYL)LYSINE; N (CARBOXYMETHYL)LYSINE; PLACEBO; SERUM AMYLOID A; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; AGED; ARTICLE; CARBOHYDRATE ANALYSIS; CHRONIC INFLAMMATION; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; ENDOTHELIAL DYSFUNCTION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; URINARY EXCRETION; URINE LEVEL;

AGED; BIOLOGICAL MARKERS; CELL ADHESION MOLECULES; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; ENDOTHELIAL CELLS; ENDOTHELIUM; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; MALE; MIDDLE AGED; THIAMINE; TREATMENT OUTCOME;

EID: 84863654466     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0040427     Document Type: Article

References (16)

1. Ritz E, Rychlik I, Locatelli F, Halimi S, (1999) End-stage renal failure in type 2 diabetes: A medical catastrophe of worldwide dimensions. Am J Kidney Dis. 34: 795-808.
2. Babaei-Jadidi R, Karachalias N, Ahmed N, Battah S, Thornalley PJ, (2003) Prevention of incipient diabetic nephropathy by high-dose thiamine and benfotiamine. Diabetes. 52: 2110-2120.
3. Karachalias N, Babaei-Jadidi R, Rabbani N, Thornalley PJ, (2010) Increased protein damage in renal glomeruli, retina, nerve, plasma and urine and its prevention by thiamine and benfotiamine therapy in a rat model of diabetes. Diabetologia. 53: 1506-1516.
4. Hammes HP, Du X, Edelstein D, Taguchi T, Matsumura T, et al. (2003) Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat Med. 9: 294-299.
5. Rabbani N, Alam SS, Riaz S, Larkin JR, Akhtar MW, et al. (2009) High-dose thiamine therapy for patients with type 2 diabetes and microalbuminuria: A randomised, double-blind placebo-controlled pilot study. Diabetologia. 52: 208-212.
6. Alkhalaf A, Klooster A, van Oeveren W, Achenbach U, Kleefstra N, et al. (2010) A double-blind, randomized, placebo-controlled clinical trial on benfotiamine treatment in patients with diabetic nephropathy. Diabetes Care. 33: 1598-1601.
7. Steffes MW, (1999) Glomerular lesions of diabetes mellitus: Preventable and reversible. Nephrol Dial Transplant. 14: 19-21.
8. Teerlink T, Barto R, Ten Brink HJ, Schalkwijk CG, (2004) Measurement of nepsilon-(carboxymethyl) lysine and nepsilon-(carboxyethyl) lysine in human plasma protein by stable-isotope-dilution tandem mass spectrometry. Clin Chem. 50: 1222-1228.
9. Scheijen JL, van de Waarenburg MP, Stehouwer CD, Schalkwijk CG, (2009) Measurement of pentosidine in human plasma protein by a single-column high-performance liquid chromatography method with fluorescence detection. J Chromatogr B Analyt Technol Biomed Life Sci. 877: 610-614.
10. Xue M, Qian Q, Adaikalakoteswari A, Rabbani N, Babaei-Jadidi R, et al. (2008) Activation of NF-E2-related factor-2 reverses biochemical dysfunction of endothelial cells induced by hyperglycemia linked to vascular disease. Diabetes. 57: 2809-2817.
11. Thornalley PJ, Babaei-Jadidi R, Al AH, Rabbani N, Antonysunil A, et al. (2007) High prevalence of low plasma thiamine concentration in diabetes linked to a marker of vascular disease. Diabetologia. 50: 2164-2170.
12. Stirban A, Negrean M, Stratmann B, Gawlowski T, Horstmann T, et al. (2006) Benfotiamine prevents macro- and microvascular endothelial dysfunction and oxidative stress following a meal rich in advanced glycation end products in individuals with type 2 diabetes. Diabetes Care. 29: 2064-2071.
13. Winkler G, Pal B, Nagybeganyi E, Ory I, Porochnavec M, et al. (1999) Effectiveness of different benfotiamine dosage regimens in the treatment of painful diabetic neuropathy. Arzneimittelforschung. 49: 220-224.
14. Ashokkumar B, Vaziri ND, Said HM, (2006) Thiamin uptake by the human-derived renal epithelial (HEK-293) cells: Cellular and molecular mechanisms. Am J Physiol Renal Physiol. 291: F796-805.
15. Reidling JC, Said HM, (2005) Adaptive regulation of intestinal thiamin uptake: Molecular mechanism using wild-type and transgenic mice carrying hTHTR-1 and-2 promoters. Am J Physiol Gastrointest Liver Physiol. 288: G1127-34.
16. Bukhari FJ, Moradi H, Gollapudi P, Ju Kim H, Vaziri ND, et al. (2011) Effect of chronic kidney disease on the expression of thiamin and folic acid transporters. Nephrol Dial Transplant. 26: 2137-2144.